Rocket Pharmaceuticals- Warrants (02/09/2026) Operating Income

As of the most recent data (June 2026), RCKTW shows a operating income of $-190M. That compares with $-270M in the prior-year period — up 28.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RCKTW's operating income is now $-190M (was $-270M) — a 28.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Rocket Pharmaceuticals- Warrants (02/09/2026) is outperforming or lagging.

Tracking RCKTW's operating income over time shows whether Rocket Pharmaceuticals- Warrants (02/09/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $-190M That compares with $-270M in the prior-year period — up 28.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Rocket Pharmaceuticals- Warrants (02/09/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-190M) with ownership activity and broader fundamentals.

Rocket Pharmaceuticals- Warrants (02/09/2026)'s operating income is $-190M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.